A Smoking Cessation Trial with Lobeline Sulfate: A Pilot Study

Elbert D. Glover; Scott J. Leischow; Stephen I. Rennard; Penny N. Glover; David Daughton; John N. Quiring; F. Howard Schneider; Peter J. Mione

A Smoking Cessation Trial with Lobeline Sulfate: A Pilot Study

Elbert D. Glover, Scott J. Leischow, Stephen I. Rennard, Penny N. Glover, David Daughton, John N. Quiring, F. Howard Schneider, Peter J. Mione

Quantitative Health Sciences

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Objective: To evaluate a sublingual formulation of lobeline sulfate for smoking cessation. Methods: Random assignment of 180 healthy smokers to treatment (n=90) or placebo (n=90). Treatment was self-administering a 7.5 mg lobeline sulfate sublingual or placebo tablet 9 times per day for 6 weeks. Results: No difference in cessation efficacy between placebo and active treatment. Among highly dependent smokers who completed the trial, there was a trend for higher cessation rates in the active group. Conclusion: This pilot study failed to demonstrate smoking-cessation efficacy. However, data suggest continued studies to evaluate lobeline sulfate for smoking cessation.

Original language	English (US)
Pages (from-to)	62-74
Number of pages	13
Journal	American Journal of Health Behavior
Volume	22
Issue number	1
State	Published - Jan 1 1998

ASJC Scopus subject areas

Health(social science)
Social Psychology
Public Health, Environmental and Occupational Health

Cite this

@article{305900927c5041c788e282f1a7c2369b,

title = "A Smoking Cessation Trial with Lobeline Sulfate: A Pilot Study",

abstract = "Objective: To evaluate a sublingual formulation of lobeline sulfate for smoking cessation. Methods: Random assignment of 180 healthy smokers to treatment (n=90) or placebo (n=90). Treatment was self-administering a 7.5 mg lobeline sulfate sublingual or placebo tablet 9 times per day for 6 weeks. Results: No difference in cessation efficacy between placebo and active treatment. Among highly dependent smokers who completed the trial, there was a trend for higher cessation rates in the active group. Conclusion: This pilot study failed to demonstrate smoking-cessation efficacy. However, data suggest continued studies to evaluate lobeline sulfate for smoking cessation.",

author = "Glover, {Elbert D.} and Leischow, {Scott J.} and Rennard, {Stephen I.} and Glover, {Penny N.} and David Daughton and Quiring, {John N.} and {Howard Schneider}, F. and Mione, {Peter J.}",

year = "1998",

month = jan,

day = "1",

language = "English (US)",

volume = "22",

pages = "62--74",

journal = "American Journal of Health Behavior",

issn = "1087-3244",

publisher = "PNG Publications",

number = "1",

}

TY - JOUR

T1 - A Smoking Cessation Trial with Lobeline Sulfate

T2 - A Pilot Study

AU - Glover, Elbert D.

AU - Leischow, Scott J.

AU - Rennard, Stephen I.

AU - Glover, Penny N.

AU - Daughton, David

AU - Quiring, John N.

AU - Howard Schneider, F.

AU - Mione, Peter J.

PY - 1998/1/1

Y1 - 1998/1/1

N2 - Objective: To evaluate a sublingual formulation of lobeline sulfate for smoking cessation. Methods: Random assignment of 180 healthy smokers to treatment (n=90) or placebo (n=90). Treatment was self-administering a 7.5 mg lobeline sulfate sublingual or placebo tablet 9 times per day for 6 weeks. Results: No difference in cessation efficacy between placebo and active treatment. Among highly dependent smokers who completed the trial, there was a trend for higher cessation rates in the active group. Conclusion: This pilot study failed to demonstrate smoking-cessation efficacy. However, data suggest continued studies to evaluate lobeline sulfate for smoking cessation.

AB - Objective: To evaluate a sublingual formulation of lobeline sulfate for smoking cessation. Methods: Random assignment of 180 healthy smokers to treatment (n=90) or placebo (n=90). Treatment was self-administering a 7.5 mg lobeline sulfate sublingual or placebo tablet 9 times per day for 6 weeks. Results: No difference in cessation efficacy between placebo and active treatment. Among highly dependent smokers who completed the trial, there was a trend for higher cessation rates in the active group. Conclusion: This pilot study failed to demonstrate smoking-cessation efficacy. However, data suggest continued studies to evaluate lobeline sulfate for smoking cessation.

UR - http://www.scopus.com/inward/record.url?scp=0032330892&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032330892&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0032330892

SN - 1087-3244

VL - 22

SP - 62

EP - 74

JO - American Journal of Health Behavior

JF - American Journal of Health Behavior

IS - 1

ER -

A Smoking Cessation Trial with Lobeline Sulfate: A Pilot Study

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this